Articles from Amlogenyx Inc

NOVATO, Calif., Nov. 11, 2026 (GLOBE NEWSWIRE) -- Amlogenyx, Inc., a biotechnology company focused on developing gene therapies for Alzheimer’s disease and other neurodegenerative diseases, today announced members of the Company management team will attend the 2026 Jefferies Global Healthcare Conference in London, taking place November 16-19, 2026. The Company will host one-on-one meetings with investors throughout the conference.

NOVATO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Amlogenyx, Inc., a biotechnology company focused on developing gene therapies for Alzheimer’s disease and other neurodegenerative diseases, today announced members of the Company management team will present at the Wells Fargo 21st Annual Healthcare Conference in Boston, Mass., on Tuesday, September 8, 2026, at 3:00 PM ET. The Company will also host one-on-one meetings with investors throughout the conference.

A novel approach using a lysosomal enzyme to prevent and reverse amyloid accumulation inside as well as outside neurons, with greater potency, delivered in a one-time gene therapy

Novel and potent catalytic approach that directly clears amyloid on the inside of neurons as well as reduces amyloid plaques with the potential to be superior to monoclonal antibodies and restore neuronal function while halting or reversing disease progression